BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today annou ...
The FDA has approved Tevimbra (tislelizumab) for use in combination with chemotherapy to treat unresectable or metastatic, HER2-, PD-L1+ gastric or GEJ adenocarcinoma.
Tevimbra is also approved in the U.S. as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that doesn ...